TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10480613
Drug: L-Arginine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Arginine (5 mg/kg body weight) co-infused during the final 5 min of each exercise bout
Study: 9592304
Drug: Clarithromycin (Cla)
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin (Cla) 500 mg b.i.d and Furazolidone (Fur) 200 mg b.i.d plus CBS 240 mg b.i.d (group I A)
Study: 9592304
Drug: Clarithromycin (Cla)
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin (Cla) 500 mg b.i.d and Furazolidone (Fur) 200 mg b.i.d plus Lan 30 mg b.i.d (group I B)
Study: 9592304
Drug: Clarithromycin (Cla)
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin (Cla) 250 mg b.i.d and Furazolidone (Fur) 100 mg b.i.d plus CBS 240 mg b.i.d (group II A)
Study: 9592304
Drug: Clarithromycin (Cla)
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin (Cla) 250 mg b.i.d and Furazolidone (Fur) 100 mg b.i.d plus Lan 30 mg q.d (group II B)
Study: 6138642
Drug: HBIG plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBIG plus hepatitis B vaccine
Study: 24919974
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of all four drug classes
Study: 24919974
Drug: Drug use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug use at discharge
Study: 7858505
Drug: 7‐3‐7 arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7‐3‐7 arm (cytosine arabinoside 100 mg/m2 continuous infusion for 7 days and daunorubicin 50 mg/m2 IV day 1‐3 plus etoposide 75 mg/m2 IV days 1‐7)
Study: 7858505
Drug: 7‐3 arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7‐3 arm (cytosine arabinoside 100 mg/m2 continuous infusion for 7 days and daunorubicin 50 mg/m2 IV day 1‐3)
Study: 28096000
Drug: 5% glutamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% glutamine oral care
Study: 28096000
Drug: 2% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% chlorhexidine gluconate solution oral care
Study: 24119736
Drug: Combined immunoprophylaxis
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined immunoprophylaxis (200 IU HBIG and 5 or 10 mug yeast recombinant hepatitis B vaccine)
Study: 24119736
Drug: 10 mug
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mug hepatitis B vaccine
Study: 24119736
Drug: 5 mug
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mug hepatitis B vaccine
Study: 24119736
Drug: Combined immunoprophylaxis
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined immunoprophylaxis (5 mug and 10 mug hepatitis B vaccine)
Study: 21612742
Drug: Propiverine hydrochloride
Normalized name: propiverine hydrochloride
DrugBank: Propiverine (DB12278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propiverine hydrochloride (30 mg s.i.d.)
Study: 21612742
Drug: Propiverine hydrochloride
Normalized name: propiverine hydrochloride
DrugBank: Propiverine (DB12278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propiverine hydrochloride (15 mg t.i.d.)
Study: 11257243
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal treatment during the 4th cycle
Study: 9309267
Drug: High dosage
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dosage antimony (20 mg/kg/day)
Study: 9309267
Drug: Low dosage
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dosage antimony (5 mg/kg/day)
Study: 9309267
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (5 mg/kg/day and 20 mg/kg/day)
Study: 8214997
Drug: 1.4 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.4 g/d gammalinolenic acid in borage seed oil
Study: 2894994
Drug: metoprolol 100
Normalized name: metoprolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol 100 mg b.d.
Study: 2894994
Drug: epanolol 100
Normalized name: epanolol
DrugBank: Epanolol (DB13757)
Approvals — FDA: no, EMA: no, PMDA: no
Description: epanolol 100 mg b.d.
Study: 2894994
Drug: epanolol 200
Normalized name: epanolol
DrugBank: Epanolol (DB13757)
Approvals — FDA: no, EMA: no, PMDA: no
Description: epanolol 200 mg b.d.
Study: 31707724
Drug: Gestational diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gestational diabetes mellitus treatment (diet, monitoring, ± insulin)
Study: 31707724
Drug: Metformin (started
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (started early)
Study: 28282381
Drug: CEA blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEA blood test at a threshold of 5μg/L
Study: 28282381
Drug: CEA blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEA blood test at a threshold of 2.5μg/L
Study: 25427243
Drug: Intracoronary injection
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary injection of human umbilical cord mesenchymal stem cells (low-dose 3x10^6, mid-dose 4x10^6, high-dose 5x10^6)
Study: 23735408
Drug: Patient self-monitoring
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient self-monitoring with self-titration of antihypertensives
Study: 18584303
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (C) received oral information.
Study: 12536592
Drug: Clindamycin suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin suppository
Study: 12536592
Drug: Metronidazole suppository
Normalized name: metronidazole Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole suppository
Study: 9426669
Drug: External ultrasonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: External ultrasonic tumescent liposuction (10 minutes of preoperative ultrasound therapy)
Study: 8275064
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of high intensity and early abstinence cognitive-behavioral group psychotherapy
Study: 8275064
Drug: Weekly psychotherapy
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly psychotherapy using manual-based cognitive-behavioral therapy
Study: 25306749
Drug: Metformin 2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 2000 mg daily for 3 months
Study: 21199787
Drug: 320 mg
Normalized name: aspirin 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 320 mg magnesium/day as magnesium citrate
Study: 11431298
Drug: Cranberry-lingonberry juice
Normalized name: cranberry juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry-lingonberry juice (50 ml daily for six months)
Study: 11431298
Drug: Lactobacillus GG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus GG drink (100 ml five days a week for one year)
Study: 9923579
Drug: PcV (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: PcV (conventional phenoxymethylpenicillin tablet)
Study: 9923579
Drug: PcVsr (saliva-resistant
Approvals — FDA: no, EMA: no, PMDA: no
Description: PcVsr (saliva-resistant coated tablet)
Study: 9923579
Drug: Both formulations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both formulations (PcV and PcVsr)
Study: 3075601
Drug: Nicardipine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (40 mg/day)
Study: 3075601
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg/day)
Study: 3075601
Drug: Nicardipine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (40 mg) during acute oral test
Study: 3075601
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg) during acute oral test
Study: 10828926
Drug: Delayed surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed surgery after conservative treatment
Study: 10828926
Drug: Randomized surgical
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized surgical treatment
Study: 10828926
Drug: Randomized conservative
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized conservative treatment
Study: 8223847
Drug: Carvedilol 25-50
Normalized name: carvedilol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 25-50 mg o.d. (n = 116)
Study: 8223847
Drug: Captopril 25-50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25-50 mg o.d. (n = 117)
Study: 31599919
Drug: Ketone monoester
Normalized name: Ketonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketone monoester drink (0.45 mL/kg body weight)
Study: 28830293
Drug: Escalated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalated treatment plan (mean doses up to 95 Gy/33 fractions for tumor and 74 Gy/33 fractions for lymph nodes)
Study: 28830293
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plan
Study: 1600052
Drug: Lansoprazole 10
Normalized name: lansoprazole 100 % MISCELL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 10 mg
Study: 1600052
Drug: Lansoprazole 20
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole 20 mg
Study: 1600052
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg (morning dosing)
Study: 1600052
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg (evening dosing)
Study: 29925383
Drug: Indacaterol/glycopyrronium (IND/GLY)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol/glycopyrronium (IND/GLY) 110/50 μg once daily
Study: 29925383
Drug: Salmeterol/fluticasone (SFC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/fluticasone (SFC) 50/500 μg twice daily
Study: 26946619
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received no TENS electrode treatments.
Study: 17846391
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (ergocalciferol or cholecalciferol) with daily doses varying from 300 to 2000 IU, mean daily dose of 528 IU.
Study: 17846391
Drug: Calcium supplements
Normalized name: CALCIUM SUPPLEMENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplements (added in some trials).
Study: 9476875
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol (500 microg via small-volume metal spacer)
Study: 7637478
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin once daily (n = 176)
Study: 2795725
Drug: Doxepin 50
Normalized name: doxepin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxepin 50 mg at bedtime for the first 2 weeks, increased by 25 mg in the morning for the last week of a 3-week treatment period.
Study: 2795725
Drug: Doxepin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxepin treatment
Study: 319356
Drug: Metoclopramide, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide, 10 mg four times daily
Study: 19460254
Drug: 4-drug fixed-dose
Normalized name: 4-MIXED TRACE ELEMENTS INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-drug fixed-dose combination (4-FDC) regimen
Study: 19460254
Drug: Single tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single tablet regimen (ST)
Study: 16678649
Drug: Mixed amphetamine
Normalized name: mixed amphetamine salts 5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed amphetamine salts extended release (MAS XR) 10, 20, and 30 mg/d
Study: 16678649
Drug: Atomoxetine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine 0.5 and 1.2 mg/kg per day
Study: 8617188
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea (300 ml)
Study: 8617188
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea with milk (300 ml tea + 100 ml milk)
Study: 8617188
Drug: Black tea
Normalized name: black tea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black tea with milk (300 ml tea + 100 ml milk)
Study: 3001562
Drug: Alsactide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alsactide (10 or 100 micrograms i.v. as bolus followed by the same dose infused over 2 hours)
Study: 30909923
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D supplementation
Study: 25939333
Drug: Polymorphic Form
Normalized name: Angelica polymorpha root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymorphic Form A of ponesimod in a capsule, 20 mg
Study: 25939333
Drug: Polymorphic Form
Normalized name: Angelica polymorpha root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymorphic Form C of ponesimod in a capsule, 20 mg
Study: 25939333
Drug: Polymorphic Form
Normalized name: Angelica polymorpha root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymorphic Form C of ponesimod in a tablet, 40 mg
Study: 25939333
Drug: Polymorphic Form
Normalized name: Angelica polymorpha root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymorphic Form C of ponesimod in a capsule, 40 mg
Study: 25939333
Drug: All formulations
Normalized name: Novel Influenza-H1N1-09, all formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: All formulations of ponesimod
Study: 9227007
Drug: Chloroquine phosphate
Normalized name: Chloroquine Phosphate
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine phosphate suppository (2.5 mg/kg)
Study: 9227007
Drug: Chloroquine sulphate
Normalized name: Chloroquine sulphate
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine sulphate syrup (2.5 mg/kg)
Study: 9227007
Drug: Chloroquine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (2.5 mg/kg)
Study: 9227007
Drug: Chloroquine phosphate
Normalized name: Chloroquine Phosphate
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine phosphate suppository and chloroquine sulphate syrup
Study: 3296793
Drug: D-phenylalanine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-phenylalanine (20 mg/kg per day)
Study: 27391972
Drug: Children with
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children with inflammation (CRP > 5 mg/L) and/or malaria parasitaemia
Study: 12568409
Drug: HRT (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT (n = 151) - 2 mg estradiol valerate and 1 mg cyproterone acetate with or without vitamin D3 (100-300 IU) + 93 mg calcium as lactate/day
Study: 12568409
Drug: Non-HRT (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-HRT (n = 180) - 93 mg calcium alone or in combination with vitamin D3 (100-300 IU)/day
Study: 14508205
Drug: Amlodipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (10 mg daily)
Study: 9327716
Drug: Fosinopril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril (20 mg daily)
Study: 24397981
Drug: Ramipril 10
Normalized name: ramipril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 10 mg per day (n=82)
Study: 22851487
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine plus premeal glulisine
Study: 22851487
Drug: Twice‐daily premix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice‐daily premix 75/25 or 70/30 analog insulin
Study: 2676800
Drug: Piroxicam gel
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piroxicam gel (4 x 5 mg)
Study: 2676800
Drug: Diclofenac gel
Normalized name: diclofenac Topical Gel
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac gel (4 x 40 mg)
Study: 350328
Drug: L-tryptophan with
Normalized name: L-TRYPTOPHAN
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-tryptophan with pyridoxine and ascorbic acid
Study: 31787454
Drug: Epidural clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural clonidine 100 μg
Study: 31787454
Drug: Epidural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural fentanyl 100 μg
Study: 20720560
Drug: CoQ(10) 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoQ(10) 300 mg daily (n=93)
Study: 16085660
Drug: 0.25 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/day ganirelix (standard dose)
Study: 16085660
Drug: 2 mg/day
Normalized name: Neupro 2 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/day ganirelix (high dose)
Study: 16085660
Drug: 0.6 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg/day buserelin (long protocol)
Study: 532690
Drug: Viloxazine 50
Normalized name: viloxazine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viloxazine 50 mg three times a day during the first week followed by 100 mg three times a day during the next three weeks
Study: 532690
Drug: Amitriptyline 25
Normalized name: amitriptyline 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 25 mg three times a day during the first week followed by 50 mg three times a day during the following three weeks
Study: 30945491
Drug: Fire needle
Normalized name: Fire Out
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fire needle stimulation at Sihua acupoints combined with chemotherapy (paclitaxel + cisplatin or gemcitabine + cisplatin)
Study: 30945491
Drug: Paclitaxel combined
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel combined with cisplatin or gemcitabine plus cisplatin (chemotherapy)
Study: 28581209
Drug: Exenatide (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (continuous 72-hour intravenous infusion)
Study: 26531700
Drug: Interferon-beta treatment
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-beta treatment in overweight or obese patients (BMI≥25kg/m²)
Study: 26531700
Drug: Interferon-beta treatment
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-beta treatment in normal-weight patients (BMI<25kg/m²)
Study: 26531700
Drug: Interferon-beta treatment
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-beta treatment in overweight or obese patients (BMI>25)
Study: 21051930
Drug: CMAB009 (anti-EGFR
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMAB009 (anti-EGFR monoclonal antibody)
Study: 21051930
Drug: CMAB009 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMAB009 (100 mg/m2)
Study: 21051930
Drug: CMAB009 (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMAB009 (250 mg/m2)
Study: 21051930
Drug: CMAB009 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMAB009 (400 mg/m2)
Study: 21051930
Drug: CMAB009 (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMAB009 (multiple infusions)
Study: 19944362
Drug: Ivabradine (IVA)
DrugBank: Ivabradine (DB09083)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ivabradine (IVA) administered 12 hours after PCI, twice per day.
Study: 19944362
Drug: Metoprolol (METO)
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol (METO) administered 12 hours after PCI, twice per day.
Study: 17717928
Drug: Wuling Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wuling Capsule (WLC)
Study: 11505966
Drug: Oral-B Cross
Normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral-B Cross Action toothbrush
Study: 7998047
Drug: lisinopril 10‐40
Approvals — FDA: no, EMA: no, PMDA: no
Description: lisinopril 10‐40 mg
Study: 7998047
Drug: nifedipine 20‐80
Approvals — FDA: no, EMA: no, PMDA: no
Description: nifedipine 20‐80 mg
Study: 30275095
Drug: Benznidazole (BNZ)
Normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benznidazole (BNZ) administered to healthy male volunteers, specific dosage not mentioned.
Study: 21036512
Drug: Opioid maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid maintenance medications
Study: 21036512
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment programs
Study: 17006925
Drug: Uracil-tegafur (UFT)
Normalized name: tegafur / uracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uracil-tegafur (UFT) 300 mg/day for 1 year after surgery (n = 79)
Study: 14583715
Drug: 1.5 mL
Normalized name: Humulin 70/30 1.5 ML Pen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mL 4% atomized lidocaine
Study: 14583715
Drug: 1.5 mL
Normalized name: Humulin 70/30 1.5 ML Pen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mL 4% atomized cocaine
Study: 14583715
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL 2% lidocaine gel
Study: 10768306
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) treatment
Study: 1298089
Drug: Fansimef (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fansimef (125 mg mefloquine + 250 mg sulfadoxine + 12.5 mg pyrimethamine)
Study: 1298089
Drug: Lariam (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lariam (125 mg mefloquine)
Study: 1298089
Drug: Fansidar (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fansidar (500 mg sulfadoxine + 25 mg pyrimethamine)
Study: 1298089
Drug: Chloroquine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (300 mg)
Study: 25090110
Drug: HVTN 503
Approvals — FDA: no, EMA: no, PMDA: no
Description: HVTN 503 MRK-AD5 HIV-1 gag/pol/nef vaccine
Study: 22733022
Drug: Bolus flavopiridol
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus flavopiridol (50 mg/m²/day, Arm A)